Faeth Therapeutics (NASDAQ: FTH) has reported preliminary Phase 2 clinical results showing a confirmed objective response rate of 33% for its investigational PIKTOR treatment combined with paclitaxel in patients with advanced endometrioid endometrial cancer (EEC).
Faeth has also reported a disease control rate of 83% and preliminary median progression-free survival of 7.4 months in its ongoing PIK-201 trial. Based on the findings, the company says it plans to advance PIKTOR into a Phase 3 registrational study, subject to regulatory discussions.
Anand Parikh, CEO of Faeth, said the company believes targeting multiple components of the PI3K/AKT/mTOR pathway could provide a treatment approach for patients with advanced endometrial cancer.
PIKTOR remains investigational and is also being developed for potential use in breast cancer.
